MAXIGEN BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43 TWD | +0.47% |
|
-0.81% | -11.16% |
| Sales 2022 | 604M 18.57M | Sales 2023 | 622M 19.12M | Capitalization | 4.3B 132M |
|---|---|---|---|---|---|
| Net income 2022 | 139M 4.27M | Net income 2023 | 166M 5.1M | EV / Sales 2022 | 5.35 x |
| Net cash position 2022 | 800M 24.58M | Net cash position 2023 | 431M 13.25M | EV / Sales 2023 | 6.23 x |
| P/E ratio 2022 |
29.1
x | P/E ratio 2023 |
26.2
x | Employees | - |
| Yield 2022 |
1.05% | Yield 2023 |
-
| Free-Float | 55.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.06% | ||
| 1 week | -1.27% | ||
| Current month | -6.35% | ||
| 1 month | -4.89% | ||
| 3 months | -5.73% | ||
| 6 months | -9.32% | ||
| Current year | -11.57% |
1 week
41.80
44.30
1 month
41.8047.55
Current year
41.8049.45
1 year
41.8071.43
3 years
25.7671.43
5 years
10.9171.43
10 years
10.9171.43
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Ting Chen
CEO | Chief Executive Officer | - | 21-11-02 |
Ruei Yi Wu
DFI | Director of Finance/CFO | - | 23-03-21 |
Yi Hua Yu
DFI | Director of Finance/CFO | - | 18-06-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Xiang Lin
CHM | Chairman | - | 21-07-11 |
Xiu Yuan Li
BRD | Director/Board Member | - | 15-06-21 |
Zhen Zhen Fu
BRD | Director/Board Member | - | 21-07-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 43 | +0.47% | 33 903 |
| 24-04-23 | 42.8 | +1.06% | 83,123 |
| 24-04-22 | 42.35 | +0.71% | 124,380 |
| 24-04-19 | 42.05 | -4.32% | 367,208 |
| 24-04-18 | 43.95 | -0.11% | 81,944 |
End-of-day quote Taiwan S.E., April 22, 2024
More quotes
MAXIGEN BIOTECH INC. is a Taiwan-based company principally engaged in the manufacture and sales of biological products, the wholesale of all kinds of medical equipment, medicines, foods, masks, skin care products, as well as the manufacture and sales of chemical materials. The Company operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
Sector
Personal Products
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.57% | 117M | |
| +10.29% | 19.38B | |
| 0.00% | 17.44B | |
| +0.35% | 10.95B | |
| -5.88% | 10.46B | |
| -1.93% | 6.35B | |
| +8.90% | 5.89B | |
| -1.12% | 4.47B | |
| -8.96% | 4.2B | |
| +0.99% | 3.76B |
- Stock Market
- Equities
- 1783 Stock
